Biomedical Laboratories / Columbia Tech Ventures / /
Event
FDA Phase / /
Facility
University A. Background On March / University Institutional Biosafety Committee Application / University Institutional Biosafety Committee Policy/Operating Procedures / University Medical Surveillance Policy / /
IndustryTerm
care protocols / updated clinical protocol / human use protocols / gene transfer product / submitted protocols / protocol applications / laboratories submitting rDNA protocols / clinical trial site / /
Organization
University’s Institutional Review Board / Columbia University / National Institute of Health / Recombinant DNA Activities Committee / Institutional Review Board / National Science Advisory Board for Biosecurity / DURC Committee / Facilitating University / Institutional Biosafety Committee / Department of Health and Human Services / office of the General / Sponsored Projects Administration / Occupational Safety and Health Administration / /
Position
Biological Safety Officer for information on meeting attendance / C. Principal Investigator / Senior Biological Safety Officer / and the Secretary / DURC Agent The Principal Investigator / Principal Investigator / Biological Safety Officer / Chair / Clinical Investigator / representative / Executive Vice President for Research / Secretary / Biosafety Officer / Counsel / Research Compliance / outside consultant / The Biosafety Officer / /
Product
BSL-1 / /
PublishedMedium
the Initial Review / Molecules / /
Technology
Gene Therapy / laboratories submitting rDNA protocols / newly submitted protocols / human use protocols / IBC protocols / animal care protocols / Recombinant DNA / HGT protocol / updated clinical protocol / /
Microsoft Word - CU IBC charge February 2014.doc